Hong D - Search Results

1

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.

Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Wheler J, et al. Among authors: hong d. Cancer. 2009 Mar 1;115(5):1091-9. doi: 10.1002/cncr.24018. Cancer. 2009. PMID: 19165805 Free article.

2

2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Swisher SG, et al. Among authors: hong d. Cancer. 2004 Oct 15;101(8):1776-85. doi: 10.1002/cncr.20585. Cancer. 2004. PMID: 15386332 Free article.

3

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.

Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA. Hong D, et al. Cancer. 2005 Oct 15;104(8):1620-6. doi: 10.1002/cncr.21356. Cancer. 2005. PMID: 16118804 Free article.

4

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM. Hong DS, et al. Cancer. 2006 Sep 15;107(6):1383-90. doi: 10.1002/cncr.22125. Cancer. 2006. PMID: 16902987 Free article. Clinical Trial.

5

Improving the institutional submission and approval process for clinical research protocols in oncology.

Camacho LH, Marubio L, Purdom MA, Leonard D, Hong DS, Moulder S, Pilat SR, Kurzrock R. Camacho LH, et al. Among authors: hong ds. J Clin Oncol. 2007 Apr 20;25(12):1632-3. doi: 10.1200/JCO.2006.09.5422. J Clin Oncol. 2007. PMID: 17443009 No abstract available.

6

Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Hong DS, Angelo LS, Kurzrock R. Hong DS, et al. Cancer. 2007 Nov 1;110(9):1911-28. doi: 10.1002/cncr.22999. Cancer. 2007. PMID: 17849470 Free article. Review.

7

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.

Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R. Hong D, et al. Mol Cancer Ther. 2008 May;7(5):1001-6. doi: 10.1158/1535-7163.MCT-07-2422. Epub 2008 Apr 29. Mol Cancer Ther. 2008. PMID: 18445656

8

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.

Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Hong DS, et al. Arch Dermatol. 2008 Jun;144(6):779-82. doi: 10.1001/archderm.144.6.779. Arch Dermatol. 2008. PMID: 18559769

9

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.

Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Braiteh F, et al. Among authors: hong d. Clin Cancer Res. 2008 Oct 1;14(19):6296-301. doi: 10.1158/1078-0432.CCR-08-1247. Clin Cancer Res. 2008. PMID: 18829512 Free PMC article. Clinical Trial.

10

Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.

Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R. Vemulapalli S, et al. Among authors: hong d. Am J Hematol. 2009 Jul;84(7):408-13. doi: 10.1002/ajh.21423. Am J Hematol. 2009. PMID: 19437507 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,031 results

Search Page